Aklidinium bromide (Aclidinium bromide)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Other respiratory drugs

Included in the formulation
  • Braternis® Genuine®
    powder d / inhal. 
    AstraZeneca UK Ltd     United Kingdom
    • АТХ:

    R.03.B.B.05   Aklidinium bromide

    Pharmacodynamics:

    Inhalation preparation of prolonged action. Selectively and competitively blocks M3- muscarinic receptors, removes the bronchoconstrictive effect of acetylcholine on the smooth muscle cells of the respiratory tract, thereby causing a persistent bronchodilator effect. Due to rapid destruction in the plasma does not have systemic anticholinergic effects.

    Pharmacokinetics:

    After inhalation, the therapeutic effect reaches a maximum 30 minutes after the beginning of the reception for 2-3 hours and lasts for 12 hours.

    Systemic action on the body does not have.

    Indications:

    It is used for the treatment of chronic obstructive pulmonary disease.

    ICD-10

    X.J40-J47.J44   Other chronic obstructive pulmonary disease

    X.J40-J47.J44.9   Chronic obstructive pulmonary disease, unspecified

    Contraindications:

    Simultaneous reception with other M-holinoblokatorami, age to 18 years, individual intolerance.

    Carefully:

    Pregnancy and lactation, angle-closure glaucoma, urinary retention, renal failure, myocardial infarction, arrhythmia, lengthening interval QT, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. It is used with caution, in cases where the expected effect exceeds the risk to the fetus and newborn.

    Dosing and Administration:

    Inhalation, 322 μg 2 times a day.

    The highest daily dose: 644 mcg.

    The highest single dose: 322 mcg.

    Side effects:

    Central and peripheral nervous system: headache, insomnia, rarely - hypoesthesia, asthenia.

    Respiratory system: dysphonia, rhinitis, nasopharyngitis, throat irritation, epistaxis, productive cough.

    The cardiovascular system: rarely - a feeling of heartbeat, ventricular fibrillation.

    Digestive system: dry mouth, vomiting, gastroenteritis, rarely - caries.

    Sense organs: blurred vision.

    Musculoskeletal system: myalgia, rarely - pain in the muscles of the chest.

    Dermatological reactions: rarely - a rash.

    Urinary system: urinary tract infections, rarely - urinary retention, cystitis.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Clinically significant interactions are not described.

    Special instructions:

    The drug is not used to stop acute bronchospasm.

    During the treatment it is not recommended to drive vehicles and work with moving mechanisms.

    Instructions
    Up